(Q34366423)

1 August 2017

1 reference

title

Bcr-Abl inhibition as a modality of CML therapeutics (English)

1 reference

1 August 2017

E Buchdunger

1

1 reference

1 August 2017

A Matter

series ordinal

2

1 reference

1 August 2017

B J Druker

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

Biochimica et Biophysica Acta

1 August 2017

1 reference

1 August 2017

1551

1 reference

1 August 2017

M11-8

1 reference

1 August 2017

1

1 reference

1 August 2017

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Acute leukaemia in bcr/abl transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2801%2900022-1

7 January 2021

10.1016/S0304-419X(01)00022-1

Identifiers

DOI

1 reference

1 August 2017

1 reference